Abstract

Intuitive Surgical will post second-quarter 2026 results Post Market on July 16, 2026, and this preview outlines consensus expectations, key operating levers, and how recent developments could shape revenue, margins, and adjusted EPS into the print.

Market Forecast

Consensus for Intuitive Surgical’s current quarter points to revenue of 2.82 billion US dollars, up 20.07% year over year, and adjusted EPS of 2.50, up 29.94% year over year; EBIT is estimated at 1.08 billion US dollars, up 32.67% year over year. No formal forecast is provided for gross margin or net profit margin, though the earnings mix suggests operating leverage given EPS growth outpacing revenue growth. The company’s commercial model remains anchored by its main business lines: Products generated 2.34 billion US dollars last quarter and Services contributed 433.70 million US dollars, with management attention on placements, procedure utilization, and the expanding installed base entering Q2 2026. The most promising growth vector in recent updates has been the Ion endoluminal platform, which saw procedures rise 39% year over year in the first quarter of 2026; revenue details have not been disclosed in consensus forecasts.

Last Quarter Review

In the previous quarter, Intuitive Surgical delivered revenue of 2.77 billion US dollars (up 22.96% year over year), a gross profit margin of 66.06%, GAAP net profit attributable to the parent company of 821.00 million US dollars with a net profit margin of 29.65%, and adjusted EPS of 2.50 (up 38.12% year over year). A notable financial highlight was EBIT of 1.08 billion US dollars, up 40.30% year over year and above market estimates. On the commercial front, Products revenue reached 2.34 billion US dollars and Services revenue was 433.70 million US dollars, while total revenue grew 22.96% year over year; net profit increased 3.36% sequentially, underscoring resilient operating momentum into Q2.

Current Quarter Outlook

Main business dynamics and revenue drivers

Heading into the second quarter, revenue growth expectations of 20.07% year over year reflect three levers: placements of surgical systems, procedure-driven utilization of instruments and accessories, and installed-base Services. Products was the dominant contributor last quarter at 2.34 billion US dollars, and the revenue structure implies procedures and related consumables remain a central earnings engine; any incremental uptick in procedure volumes typically has a more direct effect on instrument and accessory revenue. Services at 433.70 million US dollars continues to scale with the installed base and system uptime requirements; the recurring nature of Services can provide partial cushioning if system placements swing with capital cycles. The forecasted 29.94% expansion in adjusted EPS against 20.07% revenue growth suggests operating leverage, aided by scale benefits in cost of goods sold and disciplined expense control. While consensus does not publish a gross margin forecast, last quarter’s 66.06% level and the 32.67% expected growth in EBIT for this quarter imply positive mix and cost absorption effects if procedure momentum remains supportive. Foreign exchange and product cost dynamics bear monitoring; however, the observed sequential increase in net profit last quarter (+3.36%) indicates a degree of earnings resilience as the company entered Q2. System placements are a watch item this quarter, particularly as hospital capital budgets normalize and as systems upgrade cycles interact with new platform interest. Maintenance of placement velocity would support near-term product revenue and create medium-term tailwinds for Services and instrument utilization. If placements skew toward higher capability configurations, mix could further boost margins.

Most promising business and near-term catalysts

Recent operating updates point to the Ion endoluminal platform as a differentiating growth contributor: procedures rose 39% year over year in the first quarter of 2026, signaling rising clinical uptake. Although revenue detail for Ion is not separately disclosed in forecasts, procedure growth is a leading indicator for instrument pull-through and capital interest, and deeper hospital engagement may expand the addressable patient cohort for minimally invasive diagnostic and therapeutic pathways. The Ion trajectory, combined with broad utilization trends in multi-port procedures, frames a constructive medium-term view of consumables growth. Across the core system portfolio, utilization remains crucial. The company’s last reported quarter featured a 16% year-over-year increase in da Vinci procedure volume, a meaningful input for instrument and accessory demand that underpins both revenue and margin. This utilization base can also influence mix, as higher-complexity cases often entail a richer instrument and accessory profile. A steady cadence of training and user expansion supports these trends; incremental training capacity and clinical education, including regional initiatives, can magnify both system attachment and utilization rates over time. Platform evolution is another tangible catalyst. Commentary from multiple institutions highlights momentum tied to the new-generation platform, with expectations that it will gradually contribute to placements and drive richer utilization as software and workflow advances propagate across clinical teams. While early in its adoption curve, even modest increases in platform penetration can add to ASP stability, spark replacement cycles, and enhance long-term Services revenue density.

Factors most likely to move the stock this quarter

Procedure growth versus expectations is likely to be the most sensitive driver for the stock on and after the print. With the Street modeling revenue of 2.82 billion US dollars and EPS of 2.50, upside or downside surprise will hinge on how procedure volumes translated into instrument and accessory revenue, and whether placements tracked with budget pacing at hospitals. A positive spread between instrument revenue and procedure growth could indicate improved utilization intensity or favorable case mix, often read constructively by investors focused on margin durability. System placements and commentary on the capital pipeline will be parsed closely, especially color around replacement cycles and the adoption trajectory for the newest platform. Investors will look for evidence that demand is broad-based geographically and that longer sales cycles have not elongated further. Any detail on backlog size, conversion rates, and hospital financing conditions would help the market gauge the durability of second-half demand and mitigate concerns about macro-sensitive capital purchases. International dynamics, including updates on China, matter for sentiment. Management previously noted that tariffs may continue to adversely impact product cost of da Vinci Xi in China, and competitive tendering dynamics remain in flux. Investors will watch for management’s quantitative or qualitative commentary about pricing, margin protection measures, and the timing and scope of local initiatives, such as regional headquarters build-outs or training centers. Clear communication that commercial execution is adapting effectively could offset some of the headline risk around cost and pricing in international markets. In the same vein, any granularity on supply chain stability and cost tailwinds or headwinds will feed into gross margin expectations for the back half of the year.

Analyst Opinions

Recent analyst opinions are predominantly positive, with approximately 90% of notes over the past six months expressing a bullish view versus about 10% bearish. The majority emphasizes robust procedure trends, platform transition opportunities, and operating leverage potential through 2026. BTIG’s Ryan Zimmerman maintained a Buy rating with a 574 US dollars price target, citing sustained momentum across the portfolio and confidence that execution supports above-trend growth into the current print. The note emphasizes the runway tied to utilization and the newer platform’s early deployment, both of which can compound instrument pull-through if hospital teams maintain steady case growth. BTIG’s stance is consistent across multiple updates in the half-year period, reinforcing the theme of dependable procedural expansion underpinning the model. Bank of America’s Travis Steed reiterated a Buy rating and a 650 US dollars price target, highlighting strong momentum and favorable expectations around the next-generation platform’s utilization ramp. The argument from this camp centers on the interplay between placements and procedure growth, suggesting that the combination should yield a multi-quarter tailwind for instrument revenue, while Services scales with the installed base. Given that consensus EPS growth of 29.94% outpaces revenue growth of 20.07%, Bank of America’s constructive margin view aligns with the broader thesis of operating leverage through 2026. Wells Fargo’s Larry Biegelsen reaffirmed a Buy with a 654 US dollars target, with the update pointing to underlying procedure resilience and a supportive cadence of capital demand. The call notes that EBIT is positioned to expand faster than revenue, consistent with the Street’s 32.67% year-over-year EBIT growth estimate for Q2 2026. This implies confidence in cost control and mix, while acknowledging that investor attention will remain on placements and how these convert into sustained Services revenue in subsequent quarters. TD Cowen’s Mathew Blackman maintained a Buy, adjusting the price target to 585 US dollars, and underscored solid first-quarter execution, rising utilization of the newest platform, and manageable international headwinds. The perspective here is pragmatic: even as some geographies present pricing and cost challenges, the broader procedural engine and commercial upgrades are expected to support near- to medium-term growth. The framing is consistent with the observed 16% year-over-year increase in procedures last quarter and the Street’s implied expectation for continued instrument demand this quarter. Goldman Sachs maintained a Buy while lowering its price target to 558 US dollars, balancing valuation discipline with a positive operational outlook. The revision acknowledges market-wide recalibrations in the healthcare equipment space while retaining conviction in the company’s ability to grow into its multiple as utilization and platform advances accumulate through the year. By contrast, a minority view from a Sell-rated note trimmed the price target to 366 US dollars, but this perspective remains in the minority and is outweighed by the preponderance of Buy ratings and Overweight stances across the period. William Blair’s Brandon Vazquez reiterated Buy opinions multiple times during the window, including a note indicating that a stapler reload recall was seen as contained and a separate assessment of strong operating momentum and global adoption tailwinds. These updates reinforce the theme that operational issues are being managed within expectations and that the broader clinical adoption environment remains constructive. The repetition of this view through the half year complements the dominant bullish chorus around procedure momentum and systems transition. Pulling these views together, the majority camp expects the July 16, 2026 result to show healthy year-over-year growth in revenue and a stronger step-up in earnings power, supported by consistent utilization trends and a measured but steady platform transition. The bullish narrative emphasizes three pillars: placements that sustain the installed base pipeline, procedures that drive instrument and accessory revenue intensity, and operating leverage that translates top-line expansion into proportionally larger EBIT and EPS gains. Analysts will watch for management’s Q2 commentary on international pricing and costs, but consensus positioning suggests these items are manageable within the scope of full-year objectives. Given the 9-to-1 tilt toward bullish recommendations, the weight of institutional opinion aligns with the current quarter’s consensus profile of 2.82 billion US dollars in revenue and 2.50 in adjusted EPS, and it anticipates that the margin framework can accommodate near-term variability in capital timing or international cost factors. In short, the Street’s majority view expects the print and guidance narrative to validate a path of solid double-digit revenue growth and faster EPS growth, aided by utilization and platform-led mix benefits through 2026.